Complete skin clearance and beyond
- PMID: 33029797
- PMCID: PMC7820967
- DOI: 10.1111/bjd.19544
Complete skin clearance and beyond
Abstract
Linked Article:
Comment on
-
Efficacy and safety of risankizumab vs. secukinumab in patients with moderate-to-severe plaque psoriasis (IMMerge): results from a phase III, randomized, open-label, efficacy-assessor-blinded clinical trial.Br J Dermatol. 2021 Jan;184(1):50-59. doi: 10.1111/bjd.19341. Epub 2020 Sep 6. Br J Dermatol. 2021. PMID: 32594522 Free PMC article. Clinical Trial.
References
-
- Schmitt‐Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology 2006; 213:327–30. - PubMed
-
- Gordon KB, Strober B, Lebwohl M et al Efficacy and safety of risankizumab in moderate‐to‐severe plaque psoriasis (UltIMMa‐1 and UltIMMa‐2): results from two double‐blind, randomised, placebo‐controlled and ustekinumab‐controlled phase 3 trials. Lancet 2018; 392:650–61. - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical